Motoneurone Disease Stroke Peripheral Neuropathy Multiple Sclerosis
Drug Platform Publications Collaborations
Our Mission Management Team Advisory Boards


CuroNZ News

CuroNZ is pleased to report high level pre-clinical results achieved in patient dog studies in collaboration with Dr Roger Clemmons, Associate professor of Neurology for animals at the University of Florida.  He has applied intra-muscular NRP injections to several patient dogs suffering from spinal cord injury, eye diseases and the dog equivalent of progressive Multiple Sclerosis (degenerative myelopathy). 

We have uploaded a video of ‘Buc’ the dog who has spinal cord injury and the dog equivalent of retinitis pigmentosa, the video shows before and after NRP walking, gait and movement.  Click to view Video. 

Since having NRP injections Buc's eyesight has not deteriorated as would normally be expected in this timeframe and as you can see on the video his gait and walking is much improved.

Lead development, Metabolic Activity and Toxicity testing

  • Testing compoundsThe pre-clinical chemical mimetic development focuses on a NRP molecule deriving from a large protein involved in vesicular protein excretion.
  • The shortest amino acid chain providing all the desired bioactivities (see background) is eleven amino acids long.
  • Amino acid modification (chemical mimetic generation) has been performed to enhance the overall physico-chemical stability of the molecule.
  • Currently, excellent stability over a timeframe of 1 year stored under subzero conditions has been achieved.
  • Metabolic activity is excellent as confirmed by ADME analysis showing a much longer half-life in human liver cells than in rat cells.

Toxicity Testing

In-house performed long-lasting toxicity studies (30 days) using peripheral administration route of the lead compound (boosts once a day) revealed no toxicity even if 100 x times the dosage of the upper efficacy dose range was applied.

NRP treated rats performed in spatial memory tests as normal as saline-injected naïve controls.

Click on the following aspects of the NRP drug platform to read more: